by mpzzqmvj | May 12, 2022 | Press Releases
– Continued advancement of lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing global pivotal study (TransportNPC™) – Phase 2 study of Trappsol® Cyclo™ for the treatment of...
by mpzzqmvj | May 9, 2022 | Press Releases
– Live video webcast with moderated fireside chat with members of the Cyclo Therapeutics leadership team and Global Principal Investigator for the Phase 3 study, Professor Caroline Hastings, MD, on Monday, May 16th at 2:00 PM ET GAINESVILLE, Fla. – Cyclo...
by mpzzqmvj | Mar 29, 2022 | Press Releases
– Live video webcast with moderated fireside chat with members from the Cyclo Therapeutics management team and featuring Key Opinion Leader, Cynthia A. Lemere, PhD on Tuesday, April 5th at 1:00 PM ET GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq:...
by mpzzqmvj | Mar 24, 2022 | Press Releases
– Collaboration with the University of the Witwatersrand, Johannesburg (“Wits”), represented by Wits Commercial Enterprise; a wholly-owned subsidiary of the University mandated to manage and commercialize the University’s Intellectual Property;...
by mpzzqmvj | Mar 23, 2022 | Press Releases
– Live webcast fireside chat on Wednesday, March 30th at 12:30 PM ET GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing...
by mpzzqmvj | Mar 14, 2022 | Press Releases
– Lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™) continues to progress – Company advancing Trappsol® Cyclo™ for the treatment of...
